Dear Colleagues,
Happy New Year. In the USA, it seems that labs are applying for NGSP
(National Gycohaemoglobin Standardisation Program) certification so that
the results are traceable to the DCCT method which is being chosen as the
interim reference method. What are the thoughts amongst colleagues in
non-USA hospitals and clinical trials environment. The last time I look at
ADA website, the imprecision is recommended to be 5% for manufacturer and
Level III certification; and it is 3% for Level II certification (Level II
is recommended for those doing clinical trials)? What are people doing in
their own countries, whether there is any intention in applying such a
certification? I would like to have your views on this matter.
Yan Lee, ACB member, Singapore
Email : [log in to unmask]
Fax : (65)2343775
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|